

February 10, 2021

To,
The Corporate Relations Department
The BSE Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001.
Ref:- Scrip Code:- 500126

To,
The Listing Department
The National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (East),
Mumbai – 400051
Ref:- Symbol:- PGHL

Dear Sir / Madam,

Sub:- Unaudited Financial Results for the quarter ended December 31, 2020

We are pleased to inform you that at the meeting of the Board of Directors of the Company held today, the Unaudited Financial Results for the quarter ended December 31, 2020 were approved.

We are enclosing herewith the following:

- a. Unaudited Financial Results for the quarter ended December 31, 2020;
- b. Press Release; and
- c. Limited Review Report in respect of the Unaudited Financial Results for the quarter ended December 31, 2020 furnished by Statutory Auditors of the Company

Kindly take the same on record and oblige.

Thanking you,
Yours faithfully,

**For Procter & Gamble Health Limited
(Formerly Merck Limited)**

MILIND
VASANT
THATTE

Digitally signed by
MILIND VASANT
THATTE
Date: 2021.02.10
17:31:05 +05'30'

**Milind Thatte
Managing Director**

PROCTER & GAMBLE HEALTH LIMITED
(formerly known as MERCK LIMITED)

Regd. Office: Godrej One, 8th Floor, Eastern Express Highway, Pirojshanagar, Vikhroli (East), Mumbai : 400 079.
CIN No. L99999MH1967PLC013726, email: investor@procterandgamble.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 31 DECEMBER 2020

(Rs. in lakhs)

Sr. No.	Particulars	(1)	(2)	(3)	(4)	(5)	(6)
		Three months ended 31st December 2020	Preceding Three months ended 30th September 2020	Corresponding Three months ended 31st December 2019	Half Year ended 31st December 2020	Six months ended 31st December 2019	Eighteen months ended 30th June 2020
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1.	Revenue from Operations	24,022.0	26,397.0	23,676.6	50,419.0	46,193.4	135,586.0
2.	Other Income	572.0	672.0	605.7	1,244.0	1,278.1	6,889.0
3.	Total income (1+2)	24,594.0	27,069.0	24,282.3	51,663.0	47,471.5	142,475.0
4.	Expenses						
	a) Cost of materials consumed	4,667.0	9,305.0	7,350.7	13,972.0	13,732.5	41,609.6
	b) Purchases of stock-in-trade	425.0	516.0	132.0	942.0	915.6	2,837.4
	c) Changes in inventories of finished goods, work-in-progress and stock in trade	1,265.0	(325.0)	538.1	940.0	1,168.8	(1,303.0)
	d) Employee benefits expense	3,349.0	3,869.0	3,023.6	7,218.0	6,050.3	18,293.0
	e) Depreciation and amortisation expense	785.0	736.0	428.4	1,521.0	833.3	2,945.0
	f) Finance Costs	19.0	24.0	-	43.0	-	-
	g) Other expenses	5,440.0	5,222.0	7,729.3	10,662.0	14,433.9	42,608.0
	Total expenses (4)	15,951.0	19,347.0	19,202.7	35,298.0	37,134.4	106,990.0
5.	Profit before exceptional items and tax (3-4)	8,643.0	7,722.0	5,079.6	16,365.0	10,337.1	35,485.0
6.	Less: Exceptional items	-	-	-	-	-	-
7.	Profit before tax (5-6)	8,643.0	7,722.0	5,079.6	16,365.0	10,337.1	35,485.0
8.	Tax expenses						
	Current Tax	2,154.0	2,034.0	1,387.5	4,188.0	2,197.5	10,278.0
	Deferred Tax	(48.0)	(93.0)	(129.0)	(141.0)	742.6	599.0
	Tax for earlier years	(251.0)	(145.0)	-	(396.0)	-	(800.0)
9.	Net Profit for the period (7-8)	6,788.0	5,926.0	3,821.1	12,714.0	7,397.0	25,408.0
	Items that will not be reclassified to profit or loss						
	i. Re-measurement (losses) on defined benefit plans	(963.0)	(27.0)	(50.0)	(990.0)	(100.0)	(1,237.0)
	ii. Income tax effect	242.0	7.0	12.6	249.0	15.4	311.0
	Total Other Comprehensive Income, net of tax	(721.0)	(20.0)	(37.4)	(741.0)	(84.6)	(926.0)
11.	Total Comprehensive Income for the period (9+10)	6,067.0	5,906.0	3,783.7	11,973.0	7,312.4	24,482.0
12.	Paid-up equity share capital (Face Value Rs 10/- each)	1,660.0	1,660.0	1,660.0	1,660.0	1,660.0	1,660.0
13.	Other equity excluding Revaluation reserve as per Balance sheet	-	-	-	-	-	88,974.0
14.	Earnings per equity share (of Rs 10/- each) *(Not annualised)						
	(a) Basic and Diluted (in Rs.)	* 40.9	* 35.7	* 23.02	* 76.6	* 44.6	153.1

Notes:

- The above financial results for the quarter and half year ended December 31, 2020 have been reviewed and recommended by the Audit Committee, and approved by the Board of Directors of the Company at their Meeting held on February 10, 2021. The statutory auditors have carried out limited review of this unaudited financials results.
- The unaudited financial results of the Company for the quarter and half year ended December 31, 2020 have been prepared in accordance with Indian Accounting Standards ("Ind AS") as prescribed under section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standard) Rules, 2015, as amended.
- The Code on Social Security, 2020 ("Code") relating to employee benefits during employment and post-employment benefits received Presidential assent in September 2020. The Code has been published in the Gazette of India. However, the date on which the Code will come into effect has not been notified. The Company will assess the impact of the Code when it comes into effect and will record any related impact in the period the Code becomes effective.
- As a result of the nationwide lockdown imposed by the Government of India in view of the Covid-19 pandemic, the operations of the Company were temporarily disrupted at its manufacturing, warehouse and distribution locations from second half of March 2020. The operations have gradually resumed in a phased manner in line with the Government directives issued from time to time. The Company's Management has evaluated the impact of this pandemic on its business operations and financial position and based on such review, there is no significant impact on the Company's assets, capital and financial resources, profitability parameters or liquidity positions as at December 31, 2020. The Management does not envisage any impact on the going concern assumption in the foreseeable future. However, the impact assessment of COVID-19 will be a continuing process given the uncertainties associated with its nature and duration.
- Effective July 1, 2020, the Company has adopted Ind AS 116, Leases and applied the standard to its Leases using the modified retrospective approach. Accordingly, the Company has not restated comparative information. This has resulted in recognising a lease liability measured at present value of the remaining lease payments and a corresponding Right-of-Use (ROU) asset as if the lease has been commenced w.e.f. 1st July 2020. The Company discounted remaining lease payments using the lessee's incremental borrowing rate as at 1st July 2020. The Company has also elected not to apply the requirements of Ind AS 116 to short term leases and leases for which underlying asset is of low value. In the results for the current period, the nature of expenses in respect of Operating lease has changed from lease rent in previous periods to depreciation cost for the right-of-use asset and finance cost for interest accrued on lease liability. The Company has therefore recognised a lease liability and a corresponding ROU asset as at 1st July 2020. The net impact of this adoption is not material on the results for the period and earning per share.
- The Company now operates under only one segment i.e. Pharmaceuticals which its continuing operations. Accordingly, no separate segment information has been provided.
- Figures for the six months ended December 31, 2019 are the balancing figures between the reported unaudited figures of the twelve months ended December 31, 2019 and six months ended June 30, 2019, which are presented in the unaudited financial result for the purpose of comparison with comparable period of current period year to date figures.
- Previous period figures have been regrouped / reclassified wherever necessary.

For Procter & Gamble Health Limited
(Formerly known as Merck Limited)

MILIND VASANT THATTE

Digital Signature
Date: 2021.02.10
10:58:42 AM

Milind Thatte
Managing Director
DIN No. 08092990

Place : Mumbai
Date : 10 February 2021
Please visit us at our website www.pghealthindia.com

PROCTER & GAMBLE HEALTH LIMITED

Balance Sheet as at 31 December 2020

	(Rs in lakhs)	
	As at December 31, 2020 [Un-audited]	As at June 30, 2020 [Audited]
Non-current assets		
(a) Property, plant and equipment	8,868	9,771
(b) Capital work in progress	3,885	2,145
(c) Investment property	312	330
(d) Right -of -use assets	962	-
(e) Other Intangible assets	15	21
(f) Financial assets		
i. Loans	134	7
ii. Other financial assets	787	776
(g) Deferred tax assets (net)	1,906	1,515
(h) Other non current assets	415	401
(i) Non current tax asset (net)	7,027	6,989
Total non-current assets	24,311	21,955
Current assets		
(a) Inventories	10,817	13,411
(b) Financial assets		
i. Trade and other receivables	7,584	9,527
ii. Cash and cash equivalents	33,902	63,569
iii. Bank balances other than (iii) above	475	340
iv. Loans	66	9
v. Other financial assets	362	401
(c) Other current assets	7,643	8,362
Total current assets	60,849	95,619
TOTAL ASSETS	85,160	117,574
<u>EQUITY AND LIABILITIES</u>		
Equity		
(a) Equity share capital	1,660	1,660
(b) Other equity	62,828	88,974
Total Equity	64,488	90,634
Non-Current Liabilities		
Financial liabilities		
i. Other non-current financial liabilities		
(a) Provisions	5,036	4,085
(b) Lease liabilities	952	-
(c) Other non-current liabilities	69	121
Total non-current liabilities	6,057	4,206
Current liabilities		
Financial liabilities		
(a) Trade payables		
(i) total outstanding dues of micro enterprises and small enterprises	418	699
(ii) total outstanding dues of creditors other than micro enterprises and small enterprises	7,421	11,697
ii. Other financial liabilities	6,076	8,563
(b) Other current liabilities	571	888
(c) Provisions	-	436
(d) Current tax liabilities (net)	129	451
Total current liabilities	14,615	22,734
TOTAL EQUITY & LIABILITIES	85,160	117,574

Procter & Gamble Health Limited

(Formerly known as MERCK LIMITED)

Cash Flow Statement

Particulars	Half year ended	18 months ended
	December 31, 2020	June 30, 2020
	[Unaudited]	[Audited]
	Rs. in lakhs	Rs. in lakhs
A. Cash Flows from Operating Activities		
Profit before tax from continuing operations	16 365	35 485
Adjustments for:		
Net unrealised foreign exchange differences	38	66
Rent equalisation reserve	----	54
Provision for doubtful debts and advances	7	(107)
Bad debts	52	----
Depreciation of property, plant and equipment	1 521	2 945
Income from letting of residential flat	(117)	(325)
Provision for employee benefits	(454)	1 472
Loss/(Profit) on sale of assets	29	325
Share-based payment to employees	59	194
Income from write back	----	(242)
Finance Cost	43	----
Interest income	(1 065)	(5 598)
Operating profit before working capital changes	16 478	34 269
Working capital adjustments:		
(Increase) in inventories	2 594	(2 075)
(Increase) in trade receivables	1 854	(2 920)
Decrease in financial and other Assets	257	1 405
Increase in trade payables	(4 565)	3 547
(Decrease) in other liabilities and provisions	(2 186)	(530)
Cash generated from operations	14 432	33 696
Income taxes paid (net)	(4 152)	(10 159)
Net cash generated from/ (used in) operating activities (A)	10 280	23 537
B. Cash Flows from Investing Activities		
Purchase and construction of property, plant and equipment	(2 945)	(2 327)
Proceeds from sale of asset	2	30
Income from letting of residential flat	117	325
Interest received	1 284	6 056
Redemption of bank deposits	----	12 381
Invested in security deposit against commitments	(5)	----
Net cash generated from investing activities (B)	(1 547)	16 464
C. Cash flow from financing activities		
Dividend paid	(38 174)	(73 325)
Dividend tax paid	----	(15 016)
Payment of lease liability	(226)	----
Net cash flow used in financing activities (C)	(38 400)	(88 341)
Net (decrease)/ increase in cash and cash equivalents (A+B+C)	(29 667)	(48 340)
Cash and cash equivalents at the beginning of the period/year	63 569	1 11 909
Cash and cash equivalents at the end of the period/year	33 902	63 569
Components of Cash and Cash equivalents:		
Cash in Hand	----	----
Balance with Banks		
In Current accounts	4 712	4 229
In Term deposits (less than 3 months maturity)	29 190	59 340
	33 902	63 569



Procter & Gamble Health Limited Announces Half Yearly Results

Sales up 3% for quarter ended December 31, 2020

Mumbai, Feb 10, 2021: Procter & Gamble Health Limited (formerly Merck Limited) announced today its financial results for the half year ended December 31, 2020. The company has recorded a total sale of ₹ 238 crores for the quarter ended December 31, 2020, up 3% vs year ago. The Profit After Tax (PAT) was ₹ 68 crores vs ₹ 38 crores year ago, driven primarily by lower travel and selling expenses due to Covid-19 pandemic. Sales for the six-month period ending December 31, 2020 were ₹ 496 crores, up by 10% vs year ago. Profit After Tax for same period was ₹ 127 Crore.

Milind Thatte, Managing Director, Procter & Gamble Health Limited said, *“The Company continues to deliver consistent sales growth driven by a sustained demand for our quality and affordable vitamins, minerals, supplements and medicinal products. With the country gradually opening up and the markets showing a steady recovery in the health category, we will continue our focus on ensuring uninterrupted supplies while doubling down our efforts to increase reach through scientific communication, portfolio consumerization, and disease awareness and education. Our ‘SEHAT’ (meaning Health) Corporate Social Responsibility (CSR) initiative continues to grow from strength-to-strength with a host of programs dedicated to public health; ranging from building capability and capacity at grass-roots, to supporting vulnerable and disadvantaged populations through our partner NGOs.”*

About Procter & Gamble Health Limited:

Procter & Gamble Health Limited (formerly Merck Limited) is one of India’s largest VMS Companies manufacturing and marketing over-the-counter vitamins, minerals, and supplements products for a healthy lifestyle and improved quality of life. Please visit www.pghealthindia.com for the latest news and information about Procter & Gamble Health Limited and its brands.

About Procter & Gamble:

P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always®, Ambi Pur®, Ariel®, Bounty®, Charmin®, Crest®, Dawn®, Downy®, Fairy®, Febreze®, Gain®, Gillette®, Head & Shoulders®, Lenor®, Olay®, Oral-B®, Pampers®, Pantene®, SK-II®, Tide®, Vicks®, and Whisper®. The P&G community includes operations in approximately 70 countries worldwide.

CONTACTS

Media Contacts - Procter & Gamble Health Limited:

- Ruchita Mehra | mehra.r@pg.com
- Paromita Kundu | kundu.p.1@pg.com

Investor Relations Contact:

- Flavia Machado | machado.f.1@pg.com

Procter & Gamble Health Limited

(Formerly known as Merck Limited)

CIN: L99999MH1967PLC013726

Registered Office: Godrej One, 8th Floor,

Pirojshanagar, Eastern Express Highway, Vikhroli East,

Mumbai 400 079 | Tel: (91-22) 6866 9000

www.pghealthindia.com

HARIBHAKTI & CO. LLP

Chartered Accountants

Independent Auditor's Review Report on quarterly and year to date Unaudited Financial Results of Procter & Gamble Health Limited (formerly known as Merck Limited) pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015

To the Board of Directors

Procter & Gamble Health Limited (formerly known as Merck Limited)

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **Procter & Gamble Health Limited** ("the Company") for the quarter ended December 31, 2020 and for the period from July 01, 2020 to December 31, 2020 ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of the company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting



HARIBHAKTI & CO. LLP

Chartered Accountants

principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Haribhakti & Co. LLP

Chartered Accountants

ICAI Firm Registration No.103523W/W100048

Hemant J. Bhatt

Partner

Membership No.: 036834

UDIN: 21036834AAAAAD9410



Place: Mumbai

Date: February 10, 2021